Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee.Cerebrovasc Dis. 2006; 22: 294-316
- Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors in Atrial Fibrillation (ATRIA) Study.JAMA. 2001; 285: 2370-2375
- Intracerebral hematomas during anticoagulant treatment.Stroke. 1990; 21: 726-730
- Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage.Neurology. 2004; 63: 1059-1064
- Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry.Stroke. 2009; 40: 394-399
- Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study.J Neurol. 2013; 260: 2046-2051
- Effect of dronedarone on cardiovascular events in atrial fibrillation.N Engl J Med. 2009; 360: 668-678
- Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361: 1139-1151
- Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study.Arch Intern Med. 1987; 147: 1561-1564
- Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.Eur Heart J. 2006; 27: 949-953
- The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.Arch Intern Med. 2004; 164: 880-884
- Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.Stroke. 1995; 26: 1471-1477
- Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365: 981-992
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365: 883-891
- Intracerebral bleeding in patients on antithrombotic agents.Semin Thromb Hemost. 2013; 39: 963-971
- Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004; 126: 287S-310S
- Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions.Stroke. 2006; 37: 256-262
- Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.Stroke. 2012; 43: 1511-1517
- Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.Stroke. 2005; 36: 1588-1593
- Sporadic and familial cerebral amyloid angiopathies.Brain Pathol. 2002; 12: 343-357
- Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.Lancet. 2010; 376: 112-123
- Risk factors for intracerebral hemorrhage in the general population: a systematic review.Stroke. 2003; 34: 2060-2065
- Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).Chest. 2008; 133: 257S-298S
- Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.N Engl J Med. 2003; 349: 1019-1026
- Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke.Neurology. 2002; 59: 193-197
- Warfarin-induced intracerebral hemorrhage associated with microbleeds.J Clin Neurol. 2008; 4: 131-133
- Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study.Neurology. 2000; 55: 947-951
- Variants at APOE influence risk of deep and lobar intracerebral hemorrhage.Ann Neurol. 2010; 68: 934-943
- Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study.Stroke. 2002; 33: 1190-1195
- A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.Chest. 2010; 138: 1093-1100
- Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.Eur Heart J. 2012; 33: 1500-1510
- Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk.Front Neurol. 2012; 3: 133
- Warfarin-related intraventricular hemorrhage: imaging and outcome.Neurology. 2011; 77: 1840-1846
- Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage.Ann Neurol. 2010; 67: 788-793
- Fast point-of-care coagulometer guided reversal of oral anticoagulation at the bedside hastens management of acute subdural hemorrhage.Neurocrit Care. 2010; 13: 321-325
- Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage.Mayo Clin Proc. 2004; 79: 1495-1500
- Management of oral anticoagulant-induced intracranial haemorrhage.Blood Rev. 1998; 12: 35-44
- Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).Chest. 2008; 133: 160S-198S
- Guidelines on oral anticoagulation (warfarin): third edition – 2005 update.Br J Haematol. 2006; 132: 277-285
- Management of warfarin-related intracerebral hemorrhage.Expert Rev Neurother. 2008; 8: 271-290
- Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?.J Thromb Haemost. 2006; 4: 963-966
- Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.Arterioscler Thromb Vasc Biol. 2010; 30: 1885-1889
- New oral anticoagulants in development.Thromb Haemost. 2010; 103: 62-70
- Factor Xa and thrombin as targets for new oral anticoagulants.Thromb Res. 2011; 127: S5-S12
- A specific antidote for dabigatran: functional and structural characterization.Blood. 2013; 121: 3554-3562
- Antidotes edge closer to reversing effects of new blood thinners.Nat Med. 2013; 19: 251
- Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.Stroke. 2011; 42: 3594-3599
- Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban.Stroke. 2013; 44: 771-778
- Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.Circulation. 2011; 124: 1654-1662
- Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage.Stroke. 2010; 41: 402-409
- Spontaneous intracerebral hemorrhage.N Engl J Med. 2001; 344: 1450-1460
- Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation.Lancet Neurol. 2012; 11: 1066-1081
- Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.Circulation. 2011; 124: 1573-1579
- Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.Thromb Haemost. 2012; 108: 217-224
- EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.Eur Heart J. 2013; 34: 2094-2106
- European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace. 2013; 15: 625-651
- Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.Clin Res Cardiol. 2013; 102: 399-412
- Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2010; 41: 2108-2129
- Current registry studies of acute ischemic stroke.Nervenarzt. 2012; 83 ([in German]): 1270-1274
Article info
Publication history
Published online: July 29, 2014
Footnotes
Disclosure Statement: R. Veltkamp has received consulting honoraria, research support, travel grants, and speakers’ honoraria from Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Roche Diagnostics Corporation, CSL Behring, St. Jude Medical, and Sanofi-Aventis. S. Horstmann is supported by an Olympia Morata Fellowship of the Medical Faculty, University of Heidelberg, Germany.
Identification
Copyright
© 2014 Published by Elsevier Inc. All rights reserved.
